Coagulative and fibrinolytic studies on postmenopausal women treated with a new non-steroidal oestrogen.
Treatment of postmenopausal women with a non-steroid oestrogen (P1496) in a dose of 50 mg a day for 2 ,days before operation for prolapse did not suppress the histochemically determined fibrinolytic activator content of the vessel wall. Neither was any change found in the concentration of P&P-complex (prothrombin, factor VII, factor X), factor VIII, antithrombin III, alpha1-antitrypsin, alpha2-macroglobulin or the inhibitors of urokinase induced plasminogen activation. Nothing suggested a thrombogenic effect of this non-steroidal oestrogenic compound.
D000368:Aged; D000991:Antithrombins / Q000032:analysis; D001777:Blood Coagulation / Q000187:drug effects*; D004341:Drug Evaluation; D004968:Estrogens, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D005167:Factor VII / Q000032:analysis; D005170:Factor X / Q000032:analysis; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008593:Menopause / Q000187:drug effects*; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism; D011516:Prothrombin / Q000032:analysis; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors; D014596:Uterine Prolapse / Q000601:surgery; D000515:alpha 1-Antitrypsin / Q000032:analysis; D000511:alpha-Macroglobulins / Q000032:analysis
D000991:Antithrombins; D004968:Estrogens, Non-Steroidal; D000515:alpha 1-Antitrypsin; D000511:alpha-Macroglobulins; D005167:Factor VII; D011516:Prothrombin; D005170:Factor X; D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator